Form 4: Dianthus Therapeutics Director Alison Frances Lawton Reports Stock Option Grant

Alison Frances Lawton, a director of Dianthus Therapeutics, reported the acquisition of stock options exercisable for 12,500 shares of common stock on May 22, 2025.

Summary

• Alison Frances Lawton, a director at Dianthus Therapeutics, Inc., filed a Form 4 on May 22, 2025.
• The report details the grant of stock options to Lawton, exercisable for 12,500 shares of common stock.
• The exercise price of the stock options is $18.36 per share.
• The options vest on the earlier of the first anniversary of the grant date or the Issuer's 2026 Annual Meeting of Stockholders, contingent upon continued service.
• The options expire on May 22, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options is a standard practice and indicates confidence in the company's future performance, but it's not a major event.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing her to work towards the company's success.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency regarding the equity incentives provided to directors.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology and pharmaceutical industries.
• The vesting schedule and exercise price are typical and designed to align the director's interests with the long-term performance of the company.
• Comparable companies like Amgen, Regeneron, and Biogen also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
• Employees may see it as a sign of the company's commitment to its leadership.

Key Dates

Keywords

Form 4, Dianthus Therapeutics, Stock Options, Director, Beneficial Ownership, Lawton, DNTH